Comparative Pharmacology
Head-to-head clinical analysis: BUTALAN versus BUTICAPS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUTALAN versus BUTICAPS.
BUTALAN vs BUTICAPS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Butalan is an ergot alkaloid derivative that acts as a partial agonist at serotonin (5-HT2B) receptors and an antagonist at alpha-adrenergic and dopamine (D2) receptors. It also inhibits prolactin secretion by stimulating dopamine receptors in the pituitary.
Butalbital, a barbiturate, acts as a GABA-A receptor agonist, enhancing inhibitory neurotransmission in the CNS; acetaminophen inhibits cyclooxygenase (COX) activity and modulates endogenous cannabinoid receptors; caffeine is a non-selective adenosine receptor antagonist.
1-2 tablets (50-100 mg butalbital, 325-650 mg acetaminophen, 40 mg caffeine) orally every 4 hours as needed, not exceeding 6 tablets per day.
500 mg orally every 8 hours.
None Documented
None Documented
4-6 hours (terminal); prolonged in renal impairment (up to 12-15 hours)
3-5 hours (prolonged in renal impairment; dose adjustment required for CrCl <30 mL/min)
Primarily renal (70% unchanged, 20% as metabolites); fecal 10%
Renal (90% as unchanged drug), biliary/fecal (10%)
Category C
Category C
Barbiturate
Barbiturate